Offer - Urjas Oil for just ₹ 1 X
Eurepa 0.5 Tablet, a prescription drug, is manufactured in various forms such as Tablet. Primarily, it is used for the treatment of Diabetes Type 2.
The right dosage of Eurepa 0.5 Tablet depends on the age, gender, and medical history of the patient. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Detailed information has been provided in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Eurepa 0.5 Tablet as well, which are listed below. Normally, these side effects of Eurepa 0.5 Tablet are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
Eurepa 0.5 Tablet's effect during pregnancy is Severe and Severe while nursing. It is important to know if Eurepa 0.5 Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Eurepa 0.5 Tablet related warnings section.
Individuals suffering from medical conditions like Diabetic Ketoacidosis, Diabetes Type 1, Heart Disease must refrain from the use of Eurepa 0.5 Tablet since this can cause severe adverse effects. Other contraindications of Eurepa 0.5 Tablet have been discussed in the sections ahead.
Besides this, Eurepa 0.5 Tablet may also have severe interaction with some medicines. See below for a complete list.
In addition to the above precautions for Eurepa 0.5 Tablet, it is important to know that it is safe while driving, and is habit-forming.
Eurepa 0.5 Tablet is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Is the use of Eurepa 0.5 Tablet safe for pregnant women?
Eurepa should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Eurepa 0.5 Tablet safe during breastfeeding?
Eurepa may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Eurepa 0.5 Tablet on the Kidneys?
There can be some harmful effects on your kidneys after taking Eurepa. If you witness any side effects, discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Eurepa 0.5 Tablet on the Liver?
Eurepa can have moderate side effects on the liver. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Eurepa 0.5 Tablet on the Heart?
Eurepa is rarely harmful for the heart.
If you are suffering from any of the following diseases, you should not take Eurepa 0.5 Tablet unless your doctor advises you to do so -
Is this Eurepa 0.5 Tablet habit forming or addictive?
Eurepa 0.5 Tablet does not cause addiction.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can comfortably use machinery or drive after taking Eurepa 0.5 Tablet since it will not make you feel sleepy.
Is it safe?
Yes, Eurepa 0.5 Tablet is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking Eurepa 0.5 Tablet for mental disorders.
Interaction between Food and Eurepa 0.5 Tablet
Due to the absence of research, it is difficult to say how Eurepa 0.5 Tablet and food will interact.
Interaction between Alcohol and Eurepa 0.5 Tablet
Taking alcohol with Eurepa 0.5 Tablet can be dangerous.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Prandin® (repaglinide)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 273